Chris Lowe, MBA
Christopher Lowe, MBA is a member of Vincerx’s board of directors. Mr Lowe has served as chief financial officer of Cortexyme, Inc., a clinical-stage biopharmaceutical company, since January 2019. Prior to that, Mr Lowe served as a partner of FLG Partners, a professional services company, from January 2015 to April 2020. Mr Lowe also served as the Managing Partner of the Innventus Fund at Innventure, a venture capital firm, from January 2017 to March 2020 and as a member of the board of directors of Innventure from August 2016 to January 2020. From January 2015 to December 2018, Mr Lowe served as chief financial officer of Sentreheart, Inc., a biotechnology company. Mr Lowe served as the interim chief executive officer and chief financial officer of Hansen Medical, a medical robotics company listed on Nasdaq prior to its acquisition by Auris Surgical Robotics in 2016, from February 2014 to July 2016. Mr Lowe served as a director for Inspyr Therapeutics, Inc., an integrated biopharmaceutical company, from September 2016 to December 2018. He also served as a director of EpiBiome, Inc., a microbiome engineering company, from May 2016 to June 2018, and as a director and chairman of the audit committee for Asante Solutions, Inc., a medical device company, from December 2014 to October 2015. Mr Lowe holds a BS in business administration from California Polytechnic State University and an MBA from St. Mary’s University, Texas.